secwatch.observer — SEC 8-K summary
======================================

Issuer:     Nkarta, Inc. (NKTX)
CIK:        0001787400
Form:       8-K
Filed at:   2024-03-21T23:59:59+00:00
Accession:  0000950170-24-034710
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Nkarta reports FY2023 net loss $117.5M; deprioritizes NKX101, advances NKX019 in autoimmune
--------------------------------------------------------------------------------

- FY2023 net loss of $117.5M ($2.40 per basic/diluted share).
- Year-end cash, equivalents & investments $250.9M; expected to fund operations into 2026.
- NKX019 lupus nephritis trial on track to dose first patient in H1 2024.
- NKX101 AML program deprioritized after CR/CRi rate 5/20 vs 4/6 in first 6 patients.
- NKX019 compressed dosing cohort in NHL; preliminary data expected mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024034710/0000950170-24-034710-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1787400/000095017024034710/nktx-20240321.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-034710

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer